Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

[New therapeutic strategies in schizophrenia: apropos of acute decompensation treated with olanzapine].

Portier A, Antonetti JF.

Encephale. 2000 Mar-Apr;26(2):89-91. French.

PMID:
10858922
2.

Olanzapine-associated priapism.

Kuperman JR, Asher I, Modai I.

J Clin Psychopharmacol. 2001 Apr;21(2):247. No abstract available.

PMID:
11270930
3.

Manic symptoms induced by olanzapine.

Lykouras L, Gournellis R, Angelopoulos E.

Eur Neuropsychopharmacol. 2001 Apr;11(2):97-8.

PMID:
11313153
4.

Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.

Martín J, Gómez JC, García-Bernardo E, Cuesta M, Alvarez E, Gurpegui M.

J Clin Psychiatry. 1997 Nov;58(11):479-83.

PMID:
9413413
5.

The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.

Gómez JC, Sacristán JA, Hernández J, Breier A, Ruiz Carrasco P, Antón Saiz C, Fontova Carbonell E.

J Clin Psychiatry. 2000 May;61(5):335-43.

PMID:
10847307
6.

Treatment of childhood-onset schizophrenia with olanzapine.

Sholevar EH, Baron DA, Hardie TL.

J Child Adolesc Psychopharmacol. 2000 Summer;10(2):69-78.

PMID:
10933117
7.
8.

[Initiation of treatment with olanzapine in a patient hospitalized at UMD].

Portier A, Christophe S.

Encephale. 2000 May-Jun;26(3):69-71. French.

PMID:
10951908
9.

Worsening of obsessive-compulsive symptoms following treatment with olanzapine.

Morrison D, Clark D, Goldfarb E, McCoy L.

Am J Psychiatry. 1998 Jun;155(6):855. No abstract available.

PMID:
9619164
10.

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.

Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM.

J Clin Psychiatry. 1997 May;58(5):205-11. Erratum in: J Clin Psychiatry 1997 Jun;58(6):275.

PMID:
9184614
11.

Safety of olanzapine.

Beasley CM Jr, Tollefson GD, Tran PV.

J Clin Psychiatry. 1997;58 Suppl 10:13-7.

12.

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD.

J Clin Psychopharmacol. 1997 Oct;17(5):407-18.

PMID:
9315992
13.

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.

Am J Psychiatry. 1997 Apr;154(4):457-65.

PMID:
9090331
14.

Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia.

Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J.

Am J Psychiatry. 2000 Jun;157(6):987-93.

PMID:
10831481
15.

Olanzapine for mixed episodes of bipolar disorder.

Zullino D, Baumann P.

J Psychopharmacol. 1999;13(2):198. No abstract available.

PMID:
10475728
16.

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.

Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S.

Am J Psychiatry. 1998 Jul;155(7):914-20.

PMID:
9659857
17.

A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.

Ho BC, Miller D, Nopoulos P, Andreasen NC.

J Clin Psychiatry. 1999 Oct;60(10):658-63.

PMID:
10549681
18.

High-dose olanzapine for treatment-refractory schizophrenia.

Sheitman BB, Lindgren JC, Early J, Sved M.

Am J Psychiatry. 1997 Nov;154(11):1626. No abstract available.

PMID:
9356581
19.
20.

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S.

Neuropsychopharmacology. 1996 Feb;14(2):111-23.

Supplemental Content

Support Center